Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for evolocumab (Repatha) for primary hyperlipidemia in adults, including heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD). It is used along with diet and statin therapy, with or without other cholesterol-lowering therapies, in patients who need additional lowering of low-density lipoprotein cholesterol (LDL-C). It is also used along with diet, alone or in combination with non-statin cholesterol-lowering therapies, in patients for whom a statin is not advisable.